$76 Billion and Counting: The Medicare Advantage Reckoning Has Begun

By Elena Pak, Credentialing Department, WCH

The Trump administration’s proposed 2027 Medicare Advantage payment rule — flat base rates at +0.09%, plus a structural ban on “unlinked” chart reviews in risk adjustment — triggered a record 47,000 public comments. It is the most consequential attempt to address MA overpayments in years, arriving alongside a Senate investigation into UnitedHealth based on 50,000 internal documents and a parallel DOJ criminal probe. Insurers warn of benefit cuts and plan exits for 35 million seniors. Patient advocates say reductions would be a choice, not a necessity. Both statements can be true — and understanding why matters for everyone operating in this market.

Key Takeaways

1. The “flat rate” headline misrepresents what CMS is actually proposing. After risk score coding is factored in, CMS actuaries project total MA payments will rise 2.5% in 2027. The fight isn’t about the base rate. It’s about whether insurers can keep inflating those risk scores through chart reviews not tied to actual patient encounters.

2. Chart reviews are the mechanism — and the numbers are staggering. Unlinked chart reviews drove an estimated $24 billion in MA overpayments in 2023 alone. CMS’s proposal to exclude diagnoses not linked to documented clinical encounters would save over $7 billion in 2027. This is a targeted surgical intervention, not a blunt funding cut.

3. The UnitedHealth investigation reframes the entire debate. A Senate probe based on 50,000 internal documents found the company deployed specialized workforces to systematically maximize risk scores — including diagnosing opioid dependence without withdrawal symptoms, and COPD without lung function testing. This is no longer a theoretical risk adjustment problem. It suggests behavior occurring at industrial scale.

4. The $76 billion isn’t abstract — it comes out of every beneficiary’s pocket. MA overpayments inflate Part B premiums for all Medicare enrollees by an estimated $15.60 per person per month in 2026. That’s $13 billion per year taxed across the entire Medicare population, including those not enrolled in MA. The cost of inaction is already being paid.

5. Benefit cuts would be a choice, not a structural inevitability. KFF research confirms MA insurers remain highly profitable. When executives warn of “very meaningful benefit reductions,” they are describing a margin decision, not a financial collapse. Providers and policymakers should hold that distinction firm.

6. The final rule drops no later than April 6, 2026. That date is the operational horizon. Everything after — network restructuring, bid development, contract negotiations — flows from what CMS finalizes then.

How a Flat Rate Became the Biggest Fight in Medicare

On January 26, 2026, CMS released its proposed 2027 Medicare Advantage payment framework. The headline figure — a base rate increase of just 0.09%, or roughly $700 million — triggered an immediate market reaction. Shares in major publicly traded payers plummeted in post-market trading, with Humana down 12%, UnitedHealth and CVS down 9%, and Elevance down 5%. The comment period closed February 25. Regulators received almost 47,000 comments — an all-time high.

But to understand what’s actually being contested, you have to look past the rate number entirely.

When considering estimated risk score trend driven by coding practices and population changes, the expected average change in payments will be 2.54%. In other words, MA plans were already going to receive substantially more money in 2027 regardless of the base rate — because they control how sick their members appear on paper, and “appearing sicker” translates directly into higher per-member payment. The 0.09% base rate is not the issue. The issue is the second half of the proposal: a structural reform of how those risk scores are calculated.

Medicare Advantage now covers more than half of all Medicare beneficiaries, meaning the integrity of its payment model has become one of the most consequential fiscal questions in American healthcare.

The Mechanism That Built a $76 Billion Problem

To appreciate what CMS is targeting, it helps to understand how MA risk adjustment actually works.

The federal government pays MA plans a monthly capitated rate for each enrollee. That rate is adjusted upward for enrollees who are sicker — the logic being that a diabetic patient with heart failure costs more to care for than a healthy 67-year-old. Plans are therefore financially incentivized to identify and document as many conditions as possible for each member. The more diagnoses, the higher the risk score. The higher the risk score, the more CMS pays.

This system works as intended when diagnoses reflect actual clinical reality. It breaks down when insurers treat diagnosis capture as a revenue strategy independent of care delivery.

Chart reviews drove an estimated $24 billion in MA overpayments in 2023, according to MedPAC. The specific mechanism CMS is now targeting: “unlinked” chart reviews — retrospective audits of medical records that add diagnoses to a member’s risk profile without those diagnoses being associated with an actual clinical encounter. A nurse reviews a chart. A coder finds a condition. That condition gets added to the risk score. The patient may never be evaluated for it, may never be treated for it, and the plan collects the payment regardless.

CMS actuaries predict excluding these unlinked diagnoses from risk scoring would save Medicare more than $7 billion in 2027. MedPAC had already recommended exactly this step in its 2025 report to Congress.

50,000 Documents and What They Showed

The policy debate does not exist in a vacuum. Two weeks before the advance notice was released, Senator Chuck Grassley published a majority staff report based on 50,000 pages of internal UnitedHealth documents — training materials, policies, software documentation, audit tools — provided under congressional oversight requests.

The findings describe a company that sent nurses to enrollees’ homes to conduct health risk assessments, employed coders to review medical records, and incentivized external providers to assess for certain conditions — all to maximize risk scores. The report documents specific practices: guiding providers to diagnose opioid dependence in patients taking prescribed opioids without withdrawal symptoms; directing diagnosis of dementia without full dementia evaluations; coding atrial fibrillation based on medication use without confirming the drug was prescribed for that condition; and diagnosing COPD without standard lung function testing.

These findings suggest practices that go beyond routine administrative error. As the company sold its insights and workforce capabilities to other MA organizations, the behaviors documented in the Senate report appear to have spread across the industry — making UnitedHealth’s conduct a systemic risk, not merely a company-specific compliance matter.

UnitedHealth is simultaneously under investigation by the Department of Justice over its MA billing practices. Kaiser Permanente affiliates separately agreed to a record $556 million DOJ settlement over upcoding allegations in January 2026. The legal exposure is real and expanding.

What $76 Billion Actually Costs

The federal government will pay an estimated $76 billion more to cover MA seniors in 2026 than it would if those same seniors were in traditional Medicare. MedPAC notes that MA plan payments are worsening Part B premium rates for all Medicare beneficiaries — driving costs up by an estimated 7.7%, or $15.60 per person per month in 2026, totaling roughly $13 billion per year. This is not a cost borne only by MA enrollees. It is shared across the entire Medicare population. Framing the overpayment problem as an “insurer vs. government” dispute misses the point: every Medicare beneficiary is already subsidizing the status quo.

The CMS proposal attempts to address this differently from the Biden-era V28 risk adjustment model — which applied a blunt, across-the-board correction that penalized smaller, regional plans that weren’t upcoding alongside those that were. The current proposal removes the financial incentive for the specific behavior driving overpayments. Plans that weren’t using unlinked chart reviews to inflate risk scores should be largely unaffected. Plans that built their business models on them will feel this materially.

The Insurer Argument — and Why It Deserves Scrutiny

The industry’s response has been to warn of benefit reductions and plan exits. UnitedHealth Group CEO Stephen Hemsley said on a January earnings call that if the advance notice is finalized, he predicts “very meaningful benefit reductions” and potentially pulling back plans from more counties. Roughly 2.9 million enrollees were forced to disenroll from their MA plan in 2026 due to plan terminations — so exits are not hypothetical.

But these warnings should be taken seriously without being accepted uncritically. Recent KFF research confirms that MA insurers remain highly profitable. The Center for Medicare Advocacy has argued directly that benefit reductions in 2027 would be a choice, not a necessity.

The accurate framing is this: insurers are warning they may choose to reduce benefits rather than absorb reduced upcoding revenue into their margins. That is a legitimate business signal. It is not the same as saying the rule makes benefit reductions structurally inevitable — and that distinction matters enormously for how policymakers and the public evaluate the industry’s opposition.

What Providers and Administrators Should Do Now

The final rate announcement comes no later than April 6, 2026. Between now and then — and for the contracting and planning cycles that follow — providers operating in MA markets should take three concrete steps.

First, model your MA revenue under multiple scenarios. Plans most exposed to the chart review exclusion are those that have most aggressively used unlinked reviews to inflate risk scores. Those plans face disproportionate margin pressure and are more likely to restructure networks, reduce supplemental benefits, or exit markets. Know which of your payer relationships fall into that category.

Second, audit your own coding and documentation practices. Providers who participate in insurer-sponsored health risk assessments or coding programs should review whether those workflows generate encounter-linked diagnoses compliant with the proposed 2027 standards. Diagnoses captured through audio-only telehealth encounters are also proposed for exclusion from risk adjustment — a change with direct implications for practices that have built remote assessment workflows around MA populations.

Third, watch the final rule for what changes from the proposal. Insurers lobbied heavily, funded research, launched ads, and submitted a record volume of comments. The Trump administration has shown willingness to act on overpayment reform — but final rules historically shift in response to industry pressure. The distance between the January proposal and the April announcement will be informative about how far CMS is prepared to go.

The program covering more than half of all Medicare beneficiaries is at a structural inflection point. The evidence base for reform has never been stronger. Whether the regulatory follow-through matches the diagnosis is the question April will answer.

Sources: CMS CY 2027 Advance Notice (January 26, 2026); Healthcare Dive, “CMS receives record comments on controversial Medicare Advantage payment proposal” (March 4, 2026); Healthcare Dive, “CMS proposes excluding chart reviews from MA risk scoring in 2027 payment rule” (January 27, 2026); MedPAC, “Medicare Advantage overpayments will total $76B this year” (January 16, 2026); Senate Judiciary Committee Majority Staff Report, “How UnitedHealth Group Puts the Risk in Medicare Advantage Risk Adjustment” (January 12, 2026); Medicare Rights Center comments on the 2027 Advance Notice (February 26, 2026); KFF Medicare Advantage research (January 28, 2026).